C07K 14/5421
Il-8
Official title: {il-8}
C07K14/5421 (Il-8) appears on 80 US grants and 92 published applications in this corpus.
Search patents in C07K- Granted patents
- 80
- Published applications
- 92
- Assignees
- 75
- Inventors
- 267
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 6 | 0 |
| 1999 | 6 | 0 |
| 2000 | 4 | 0 |
| 2001 | 3 | 0 |
| 2002 | 7 | 4 |
| 2003 | 0 | 9 |
| 2004 | 0 | 3 |
| 2005 | 0 | 1 |
| 2006 | 3 | 7 |
| 2007 | 2 | 7 |
| 2008 | 1 | 3 |
| 2009 | 2 | 6 |
| 2010 | 2 | 2 |
| 2011 | 1 | 3 |
| 2012 | 2 | 4 |
| 2013 | 2 | 3 |
| 2014 | 1 | 3 |
| 2015 | 2 | 4 |
| 2016 | 1 | 2 |
| 2017 | 1 | 6 |
| 2018 | 4 | 6 |
| 2019 | 4 | 4 |
| 2020 | 6 | 6 |
| 2021 | 2 | 1 |
| 2022 | 2 | 3 |
| 2023 | 0 | 2 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bicyclic peptide ligands specific for CD13719 May 2026US 12,630,588 B2BicycleTx Limited
- Bicyclic peptide ligands specific for CD13730 Jul 2024US 12,049,520 B2BicycleTx Limited
- Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer19 Apr 2022US 11,305,017 B2The General Hospital Corporation
- Bicyclic peptide ligand specific for CD1371 Mar 2022US 11,261,214 B2BicycleTx Limited
- Treatment of infection by human enterovirus D687 Dec 2021US 11,191,817 B2AnsunBiopharma, Inc.
- Immune cell-derived secretome20 Aug 2026US 2026/0243757 A1Agency for Science, Technology and Research
- Bicyclic peptide ligands specific for cd13720 Feb 2025US 2025/0059236 A1BicycleTx Limited
- Anti-nkp30 antibody and application thereof9 May 2024US 2024/0150460 A1Shenghe (China) Biopharmaceutical Co., Ltd.
- Enhanced-affinity anti-ecm nanobody-cytokine fusions and their applications21 Sep 2023US 2023/0295284 A1Massachusetts Institute of Technology
- A fusion proteon of stromal cell-derived factor-1 (sdf-1) and interleukin-2 (il-2) and applications thereof24 Aug 2023US 2023/0265150 A1National Chung Hsing University
Most cited
By later US patents
- Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties153US 5,362,852 APfizer Inc. · 1994
- Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides41US 6,451,543 B1Gryphon Sciences · 2002
- Antibodies specific for neutrophic chemotactic factor39US 5,698,196 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1997
- Peptide inhibitors of neutrophil activating factor induced chemotaxis28US 5,079,228 ABoard of Regents, The University of Texas System · 1992
- [ALA IL-8].sub.77 and [SER IL-8].sub.72 as Leukocyte adhesion inhibitors24US 5,451,399 AGenentech, Inc. · 1995